A CRISPR-based genome editing approach to boost beta-carotene (provitamin A) content in potato tubers by engineering the Orange gene and knocking out beta-carotene hydroxylase, targeting vitamin A deficiency in low-income populations.
This solution uses CRISPR-Cas9 and Cas12a genome editing to increase provitamin A (beta-carotene) content in potato tubers. Standard yellow-fleshed potato varieties contain primarily carotenoids such as lutein, zeaxanthin, and violaxanthin, which lack provitamin A activity, with only trace amounts of beta-carotene. By editing two key genes, the approach aims to convert potato tubers into a meaningful dietary source of vitamin A, addressing deficiency-related conditions such as night blindness in low-income populations, particularly in regions like Africa.
Editing targets:
Delivery method: Ribonucleoprotein (RNP) complexes of Cas9 or Cas12a with synthetic guide RNAs are delivered into potato protoplasts, enabling DNA-free editing without integration of foreign DNA.
Validation workflow: Mutant plants are regenerated from edited protoplasts, and tuber carotenoid profiles are quantified to assess provitamin A gains.
The approach is grounded in published proof-of-concept results from potato, rice, and cauliflower, demonstrating that Or gene variants and BCH suppression each independently increase beta-carotene in storage tissues. Current efforts focus on protoplast transformation, mutant regeneration, and carotenoid profiling. The project is seeking funding support for RNP reagents, mutant generation and screening, analytical work, and partial postdoctoral support, positioning the technology at an early-to-mid stage of translational development toward biofortified potato varieties.
The University of Maryland is the state's flagship public research university in College Park, serving a large student body and offering comprehensive academic and research programs. Industry engages through an adjacent research park, shared prototyping facilities, and dedicated corporate partnership channels, plus joint pathways to a medical campus for clinical and regulatory engagement. Its Washington–Baltimore location places partners near federal agencies, national labs, and prime contractors, while a statewide extension network supports collaboration with companies. Research is backed by competitive federal funding from agencies such as NSF, NIH, DoD, DOE, NASA, and USDA, and coordinated commercialization services advance IP, startup formation, licensing, and industry-sponsored research.